Results 121 to 130 of about 29,271 (207)

Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study. [PDF]

Blood Adv
Autore F, Tedeschi A, Benevolo G, Danesin N, Giannarelli D, Rizzi R, Cencini E, Mattiello V, Ferrarini I, Pasquale R, Del Giudice I, Ferrari A, Bullo M, Rossini B, Motta M, Marino D, Innocenti I, Stirparo L, Petrilli D, Musto P, Peri V, Zamprogna G, Hohaus S, Frustaci AM, Piazza F, Ferrero S, Laurenti L.   +26 more
europepmc   +1 more source

Longitudinal gut microbiome dynamics are associated with clinical outcome and toxicity during ibrutinib therapy. [PDF]

Gut Microbes
Morineau N, Tessoulin B, Guimard T, Papin M, Roquilly A, Le Gouill S, Montassier E.   +6 more
europepmc   +1 more source

Epigenetic Compound Library Screen Identifies Ibrutinib as an Inhibitor of Ovarian Clear Cell Carcinoma Viability. [PDF]

Cancer Med
Ma Y, Dickson KA, Sarker FA, Alghalayini A, Field NR, Xie T, Skipper TS, Karafotias A, Briscas S, Yee C, Ford CE, Bowden NA, Tran N, Marsh DJ.   +13 more
europepmc   +1 more source

A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases

Journal of Comparative Effectiveness Research
Aim: Real-world evidence comparing healthcare resource utilization (HRU) and costs between ibrutinib and acalabrutinib, two Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL ...
Kerry A Rogers, Benyam Muluneh, Zaina P Qureshi, Jinghua He, Alex Bokun, Zhijie Ding, Marie-Helene Lafeuille, Priyanka Gogna, Bruno Emond, Michael Fradley   +9 more
doaj   +1 more source

Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis. [PDF]

Oncologist
Mushtaq A, Ahmed EN, Aljumaa R, E'mar AR, Badwan O, Ashruf O, Elshaer A, Shaik A, Baroudi M, Moudgil R, Mustafa Ali MK.   +10 more
europepmc   +1 more source

Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study. [PDF]

Cancers (Basel)
Molica S, Scalzulli PR, Scarfò L, Minoia C, Murru R, Sportoletti P, Albano F, Di Renzo N, Sanna A, Laurenti L, Massaia M, Cassin R, Coscia M, Patti C, Pennese E, Tafuri A, Chiarenza A, Galieni P, Perbellini O, Selleri C, Califano C, Ferrara F, Cuneo A, Murineddu M, Palumbo G, Scortechini I, Tedeschi A, Trentin L, Varettoni M, Pane F, Merli F, Morello L, Musuraca G, Tani M, Ibatici A, Palma M, Arienti D, Mauro FR.   +37 more
europepmc   +1 more source

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: Extended phase 3 results from RESONATE-2 [PDF]

, 2018
Bartlett, Nancy L, et al.,
core   +1 more source

Richter-like transformation of CLL/SLL after a temporary hold of ibrutinib: A case report. [PDF]

Leuk Res Rep
Chiang TL, Frater J, Cashen A.
europepmc   +1 more source

Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies. [PDF]

ESMO Open
Zhu J, Li J, Tam CS, Wang L, Xu J, Zhang J, Khanna P, Qiu L.   +7 more
europepmc   +1 more source

Economic Evaluation of Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa. [PDF]

Appl Health Econ Health Policy
Woudberg R, Sinanovic E.
europepmc   +1 more source